August 2016 ARTICLE LIST >>
PharmaTutor (August - 2016)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 8)
Received On: 01/03/2016; Accepted On: 09/04/2016; Published On: 01/08/2016
AUTHORS:
Akansha Bhandari 1, Nitisha Bhandari 2*
1 Shri Guru Ram Rai Institute of Technology and Science, Patel Nagar, Dehradun, India
2Graphic Era University, Dehradun, India
* nitishabhandari89@gmail.com
ABSTRACT: Modern era diseases bring more challenges and hurdles to the rational drug targeting. However chemotherapy is the most affected area as most reports are related to antibiotics resistance. Although some successes are accounted as new molecules and new structures are keep on synthesizing or either isolated. One such example is Teixobactin which is isolated for Eleftheria terrae, which was found to be active against Staphylococcus and Mycobacterium bacteria. The story of Teixobactin isolation could open new horizon and opportunistic ways for future designing of useful drugs against these resistance bacteria. In the similar context we tried to compile the relevant paper that was published in nature in 2015 into a commentary based critical review.
How to cite this article: Bhandari A, Bhandari N; Emergence of Novel Peptide molecular class as Antibiotics; PharmaTutor; 2016; 4(8); 23-26
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Thomsen M: The Selfish Gene: The Broken Promises of the Human Genome Project. In: The Daily Beast. 2013.
2. Negi A, Pandey AK, Joshi G, Agnihotri V: Impact of Protein Tyrosine Phosphate on Cancer Metastasis: An Overview.
3. Negi A, Gill B, Anand S; Tilling: Versatile Reverse Genetic Tool; PharmaTutor; 2014; 2(1); 26-32.
4. Negi A, Singla R, Singh V; Indole Based Alkaloid in Cancer: An Overview; PharmaTutor; 2014; 2(1); 76-82.
5. Singla R, Singh V, Negi A; Synthetic Indole Alkaloids in Cancer: An Overview.
6. Negi A, Gill B: Success Stories of Enolate Form of Drugs; PharmaTutor; 2013; 1(2); 45-53.
7. Negi A: Anaphylactic Shock: Shocking Error of Immune System! PharmaTutor 2013; 1(2); 12-16.
8. Joshi MP: Country and regional level advocacy and coalition-building against antimicrobial resistance. In: 143rd APHA Annual Meeting and Exposition (October 31-November 4, 2015): 2015. APHA.
9. Nami Y, Haghshenas B, Abdullah N, Barzegari A, Radiah D, Rosli R, Khosroushahi AY; Probiotics or antibiotics: future challenges in medicine; Journal of medical microbiology; 2015; 64(2); 137-146.
10. Frieden TR; The future of public health; New England Journal of Medicine; 2015; 373(18); 1748-1754.
11. Alsaeed A, Blondeau JM; Antibiotic resistance in hospitals; Future microbiology; 2015; 10(3); 303-307.
12. Littmann J, Buyx A, Cars O; Antibiotic resistance: An ethical challenge; International Journal of Antimicrobial Agents; 2015; 46(4); 359-361.
13. Phimister EG, Arias CA, Murray BE; A new antibiotic and the evolution of resistance; New England Journal of Medicine; 2015; 372(12); 1168-1170.
14. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schäberle TF, Hughes DE, Epstein S; A new antibiotic kills pathogens without detectable resistance; Nature; 2015; 517(7535); 455-459.
15. Sham L-T, Butler EK, Lebar MD, Kahne D, Bernhardt TG, Ruiz N; MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis; Science; 2014; 345(6193); 220-222.
16. Mohammadi T, van Dam V, Sijbrandi R, Vernet T, Zapun A, Bouhss A, Diepeveen‐de Bruin M, Nguyen‐Distèche M, de Kruijff B, Breukink E; Identification of FtsW as a transporter of lipid‐linked cell wall precursors across the membrane; The EMBO journal; 2011; 30(8); 1425-1432.
.png)
